• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Investig Med . EXPRESS: Comparing Different Viral Strains in Identifying Risk Factors for the Development of Venous Thromboembolism in Hospitaliz

tetano

Editor, Senior Moderator
J Investig Med


. 2025 Feb 20:10815589251320042.
doi: 10.1177/10815589251320042. Online ahead of print. EXPRESS: Comparing Different Viral Strains in Identifying Risk Factors for the Development of Venous Thromboembolism in Hospitalized COVID-19 Patients

Harsimran Panesar[SUP] 1 2 [/SUP], Ruchi Raval[SUP] 1 [/SUP], Amber Wai-San Chan[SUP] 1 [/SUP], Jana Tancredi[SUP] 3 [/SUP], Gregory Simonian[SUP] 1 3 [/SUP], David J O'Connor[SUP] 1 3 [/SUP]



Affiliations
Abstract

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, there have been nearly seven million deaths associated with COVID-19 and over thirteen billion total vaccine doses administered worldwide. This study aimed to evaluate the patient demographics and laboratory values that might help predict individuals at risk of having a DVT formation while hospitalized with COVID-19, focusing on the four major strains alongside the associated vaccination availability periods in the United States to devise risk stratification and management algorithms. This retrospective cohort study analyzed 4,429 COVID-19 positive patients admitted to a single, tertiary care institution from March 2020 - February 2024 who underwent venous duplex ultrasound due to clinical suspicion. Results: It was found that active chemotherapy treatment, higher weight (77.0 vs. 84.0 kg), and longer LOS to first duplex (5 vs. 10 days) were independent predictors of mortality. Additionally, men, older age (68 vs. 70 years old), medical history of DVTs, and longer LOS to first duplex (5 vs. 8 days) were prognostic for DVT formation. More importantly, the prevalence of DVT was not statistically different between each COVID-19 wave, despite diminished mortality and morbidity overtime. These factors should raise clinical suspicion for DVT formation and mortality among physicians. This study also demonstrated many non-predictive variables including COVID-19 as the principal diagnosis, BMI, smoking status, history of atrial fibrillation, stroke, CAD, vaccination status, and all laboratory values. This study helps establish a critical foundation to analyze trends of anticoagulant and systemic corticosteroid use in this COVID-19 patient population.

Keywords: COVID-19; Pulmonary Embolism; Thrombosis; Ultrasonography, Doppler; Vascular

 
Back
Top Bottom